The city of Washington, District Of Columbia, currently has 13 active clinical trials seeking participants for Alzheimer's Disease research studies.
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/19/2024
Locations: Georgetown University, Washington, District of Columbia +1 locations
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Alzheimer's Disease Neuroimaging Initiative 4
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/19/2024
Locations: Georgetown University, Washington, District of Columbia +1 locations
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
Recruiting
The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/29/2024
Locations: Re:Cognition Health - Fairfax, Washington, District of Columbia
Conditions: Alzheimer Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Recruiting
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.
Gender:
All
Ages:
Between 40 years and 64 years
Trial Updated:
05/23/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Late Onset Alzheimer's Disease
Recruiting
The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.
Gender:
All
Ages:
55 years and above
Trial Updated:
05/15/2024
Locations: University of Washington, Washington, District of Columbia
Conditions: Alzheimer Disease
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Recruiting
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
05/08/2024
Locations: Georgetown University, Washington, District of Columbia +1 locations
Conditions: Early Alzheimer's Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
Recruiting
This is a phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to phase 2B. In phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants. In the event that the stage gate for phase 2B is reached, the... Read More
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
04/26/2024
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Alzheimer Disease
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerabili... Read More
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
02/06/2024
Locations: Georgetown University, Washington, District of Columbia +1 locations
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Brain Health & the Microbiome
Recruiting
The GW SMHS supports research in complementary and integrative approaches to treatment of sickness and disease and for health promotion. Sometimes, research may involve asking questions of patients, students, and health providers. In this study, individuals are being asked to participate in this study as either 1) a healthy volunteer, 2) a person with Mild Cognitive Impairment (MCI), or 3) a person with early Alzheimer's disease (eAD). We are trying to learn more about if the gut microbiome (the... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
09/08/2023
Locations: George Washington University School of Medicine & Health Sciences, Washington, District of Columbia
Conditions: Mild Cognitive Impairment, Mild Dementia, Alzheimer Disease 1
DECIDE: Dyads and Families
Recruiting
The purpose of this study is to design and test a decision-making program that is tailored to support adult daughters making healthcare decisions for their parents who are living with memory loss to improve the quality of life of African American families. There are two phases of this research study. The first phase will collect information by surveys and/or interviews. The surveys and interviews will ask questions about demographics (e.g., age, race/ethnicity), culture, health, family dynamics... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/02/2023
Locations: Zeta Phi Beta Sorority, Inc., Washington, District of Columbia
Conditions: Dementia, Alzheimer Disease, Caregiver Burden
The A-LIST WMM Insights Series
Recruiting
The main purpose of the Study is to develop an understanding over time and through multiple research projects, including surveys, interviews, online focus groups, and other primary research methodologies (A-LIST Research Projects) on what matters most to individuals concerned about brain health and those with and/or affected by Alzheimer's disease and other dementias, including caregivers.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/13/2022
Locations: UsAgainstAlzheimer's, Washington, District of Columbia
Conditions: Alzheimer Disease, Dementia, Mild Cognitive Impairment
Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease
Recruiting
The purpose of this study is to determine whether daily treatment with this new treatment approach, called COT would be effective in protecting the memory and brain regions of people who are already showing signs of memory loss.
Gender:
All
Ages:
Between 55 years and 95 years
Trial Updated:
05/12/2022
Locations: Clinics of Dr. Edwin Chapman @ MHDG, Washington, District of Columbia +2 locations
Conditions: Mild Cognitive Impairment, Early Alzheimer's Disease, Memory Impairment